Literature DB >> 32310166

Association of Cerebral Microbleeds with Cognitive Decline: A Longitudinal Study.

Lin Li1, Dan-Hong Wu2, Hong-Qi Li3, Lin Tan1, Wei Xu1, Qiang Dong3, Lan Tan1, Jin-Tai Yu3.   

Abstract

BACKGROUND: The role of cerebral microbleeds (CMBs) in cognitive impairment remains controversial.
OBJECTIVE: To investigate the possible links between the presence, progression, number, and location of CMBs and cognition.
METHODS: We assessed 792 subjects from the Alzheimer's Disease Neuroimaging Initiative who underwent both brain 3 Tesla MRI scans and cognitive testing. The association between CMBs and cognitive change was explored using linear mixed-effects models (LME).
RESULTS: Presence and number of CMBs were associated with memory (β= -0.03, p = 0.015; β= -0.01, p = 0.003), executive function (β= -0.04, p = 0.010; β= -0.01, p = 0.014), and global cognitive function (β= -0.06, p = 0.025; β= -0.03, p < 0.001). Progression of CMBs showed significant negative associations with executive function (β= -0.05, p = 0.025) and global cognitive function (β= -0.12, p = 0.015). The relations with cognitive performance (memory, executive function and global cognitive function) were mainly driven by lobar CMBs (β= -0.03, p = 0.041; β= -0.04, p = 0.010; β= -0.07, p = 0.029, respectively), especially those located in temporal lobe (β= -0.08, p = 0.027; β= -0.13, p = 0.001; β= -0.26, p < 0.001, respectively). Furthermore, white matter hyperintensities may mediate the association between CMBs and cognition.
CONCLUSION: The presence, progression, number, and location of CMBs, especially those located in temporal lobe, are associated with cognitive decline. These findings suggest CMBs play a role in cognitive impairment.

Entities:  

Keywords:  Alzheimer’s disease; cerebral amyloid angiopathy; cerebral microbleeds; cognitive function

Mesh:

Year:  2020        PMID: 32310166     DOI: 10.3233/JAD-191257

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  5 in total

1.  Alzheimer resemblance atrophy index, BrainAGE, and normal pressure hydrocephalus score in the prediction of subtle cognitive decline: added value compared to existing MR imaging markers.

Authors:  Panteleimon Giannakopoulos; Marie-Louise Montandon; François R Herrmann; Dennis Hedderich; Christian Gaser; Elias Kellner; Cristelle Rodriguez; Sven Haller
Journal:  Eur Radiol       Date:  2022-04-29       Impact factor: 5.315

Review 2.  Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease.

Authors:  Dallas P Veitch; Michael W Weiner; Paul S Aisen; Laurel A Beckett; Charles DeCarli; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Susan M Landau; John C Morris; Ozioma Okonkwo; Richard J Perrin; Ronald C Petersen; Monica Rivera-Mindt; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; Duygu Tosun; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2021-09-28       Impact factor: 16.655

3.  New Remote Cerebral Microbleeds on T2*-Weighted Echo Planar MRI After Intravenous Thrombolysis for Acute Ischemic Stroke.

Authors:  Bartosz Jabłoński; Anna Gójska-Grymajło; Daria Ossowska; Edyta Szurowska; Adam Wyszomirski; Bartłomiej Rojek; Bartosz Karaszewski
Journal:  Front Neurol       Date:  2022-02-15       Impact factor: 4.003

4.  Clinical impact of microbleeds in patients with Alzheimer's disease.

Authors:  Daniel Vázquez-Justes; Iván Aguirregoicoa; Leandre Fernandez; Anna Carnes-Vendrell; Faride Dakterzada; Laura Sanjuan; Andreu Mena; Gerard Piñol-Ripoll
Journal:  BMC Geriatr       Date:  2022-09-29       Impact factor: 4.070

5.  Cerebral small vessel disease burden and longitudinal cognitive decline from age 73 to 82: the Lothian Birth Cohort 1936.

Authors:  J M Wardlaw; I J Deary; O K L Hamilton; S R Cox; J A Okely; F Conte; L Ballerini; M E Bastin; J Corley; A M Taylor; D Page; A J Gow; S Muñoz Maniega; P Redmond; M Del C Valdés-Hernández
Journal:  Transl Psychiatry       Date:  2021-07-06       Impact factor: 6.222

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.